MADRID, April 6, 2017 /PRNewswire/ --
PharmaMar (MCE: PHM), a leading biopharmaceutical company focused on the discoveryand development of innovative marine-derived anticancer drugs, today announced that it will host a Research and Development Event in New York on Monday, April 24th, 2017, from 10:30
(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )
The presentation will be webcast simultaneously on the calendar section of the Company's Events Calendar page of the website at http://www.pharmamar.com
A webcast replay will be available on the PharmaMar website for 30 days following the call by visiting the Events Calendar page of the company's website at http://www.pharmamar.com.
Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com
MEDIA CONTACTS : Media Relations Manager (Paula Fernández +34-638-79-62-15 – firstname.lastname@example.org ) and Investor Relations (+34-914444500)
Subscribe to our Free Newsletters!
Learn the basics about diabetes and how to bring it under control with turmeric, an highly ...
Antioxidants are artificial or natural components that help protect the human body from the damage ...
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...View All